Recent Advances of Nanocarriers for Effective Delivery of Therapeutic Peptides

Atabakhshi‐Kashi, Mona; Geranpayehvaghei, Marzieh; Wang, Shaobin; Akhbariyoon, Hamidreza; Taleb, Mohammad; Zhang, Yinlong; Khajeh, Khosro; Nie, Guangjun

doi:10.33218/001c.13444

Cited by 4 publications

(4 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These methods require highly trained laboratory personnel, BSL-3 facilities, and practices. Novel detection methods are based on diverse targets, from detection based on DNA ( Pal and Alocilja, 2010 ; Hao et al, 2011 ; Kaittanis et al, 2011 ; Chen et al, 2020 ), chemical reactions ( Boyer et al, 2007 ; Duriez et al, 2009 ; Čapek et al, 2010 ; Kuklenyik et al, 2011 ), antibodies ( De et al, 2002 ; Biagini et al, 2006 ; Campbell and Mutharasan, 2006 ; McGovern et al, 2007 ; Hao et al, 2009 ; Mwilu et al, 2009 ; Tang et al, 2009 ; Zahavy et al, 2010 ; Wang, 2013 ; Atabakhshi-Kashi et al, 2020 ), phages ( Schuch et al, 2002 ; Fujinami et al, 2007 ), peptides ( Acharya et al, 2007 ; Park et al, 2009 ), aptamers ( Alibek and Handelman, 1999 ; Huan et al, 2009 ; Cella et al, 2010 ; Oh et al, 2011 ; Kim et al, 2013 ) or even DNA-peptide chimeras ( Zhang and Appella, 2007 ; Kim et al, 2015 ; Wang D-B. et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

Anthrax revisited: how assessing the unpredictable can improve biosecurity

Sabra,

Krin,

Romeral

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

B. anthracis is one of the most often weaponized pathogens. States had it in their bioweapons programs and criminals and terrorists have used or attempted to use it. This study is motivated by the narrative that emerging and developing technologies today contribute to the amplification of danger through greater easiness, accessibility and affordability of steps in the making of an anthrax weapon. As states would have way better preconditions if they would decide for an offensive bioweapons program, we focus on bioterrorism. This paper analyzes and assesses the possible bioterrorism threat arising from advances in synthetic biology, genome editing, information availability, and other emerging, and converging sciences and enabling technologies. Methodologically we apply foresight methods to encourage the analysis of contemporary technological advances. We have developed a conceptual six-step foresight science framework approach. It represents a synthesis of various foresight methodologies including literature review, elements of horizon scanning, trend impact analysis, red team exercise, and free flow open-ended discussions. Our results show a significant shift in the threat landscape. Increasing affordability, widespread distribution, efficiency, as well as ease of use of DNA synthesis, and rapid advances in genome-editing and synthetic genomic technologies lead to an ever-growing number and types of actors who could potentially weaponize B. anthracis. Understanding the current and future capabilities of these technologies and their potential for misuse critically shapes the current and future threat landscape and underlines the necessary adaptation of biosecurity measures in the spheres of multi-level political decision making and in the science community.

show abstract

Section: Resultsmentioning

confidence: 99%

Anthrax revisited: how assessing the unpredictable can improve biosecurity

Sabra,

Krin,

Romeral

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…These methods require highly trained laboratory personnel, BSL-3 facilities, and practices. Novel detection methods are based on diverse targets, from detection based on DNA (Pal and Alocilja, 2010;Hao et al, 2011;Kaittanis et al, 2011;Chen et al, 2020), chemical reactions (Boyer et al, 2007;Duriez et al, 2009;Čapek et al, 2010;Kuklenyik et al, 2011), antibodies (De et al, 2002;Biagini et al, 2006;Campbell and Mutharasan, 2006;McGovern et al, 2007;Hao et al, 2009;Mwilu et al, 2009;Tang et al, 2009;Zahavy et al, 2010;Wang, 2013;Atabakhshi-Kashi et al, 2020), phages (Schuch et al, 2002;Fujinami et al, 2007), peptides (Acharya et al, 2007;Park et al, 2009), aptamers Huan et al, 2009;Cella et al, 2010;Oh et al, 2011;Kim et al, 2013) or even DNA-peptide chimeras (Zhang and Appella, 2007;Kim et al, 2015;Wang D-B. et al, 2021).…”

Section: Detectionmentioning

confidence: 99%

Insights In Biosafety & Biosecurity 2022/2023: Novel Developments, Current Challenges, and Future Perspectives

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

“…While these natural agents have shown effective-ness in targeting hypoxia in preclinical models, the clinical translation of natural agents for targeting tumor hypoxia remains limited due to poor bioavailability profiles of these agents [76]. To overcome these barriers, various strategies have been employed, including the use of nanoparticles, liposomes, and prodrug formulations; however, well-designed clinical trials are needed to establish the safety, efficacy, and optimal dosing regimens of these natural agents [77,78].…”

Section: Other Strategies Targeting Tumor Hypoxiamentioning

confidence: 99%

Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma

Rao

Roth

Bryan

et al. 2023

Cancers

View full text Add to dashboard Cite

Hypoxia-inducible factor 1 alpha (HIF-1α) is a transcription factor that regulates the cellular response to hypoxia and is upregulated in all types of solid tumor, leading to tumor angiogenesis, growth, and resistance to therapy. Hepatocellular carcinoma (HCC) is a highly vascular tumor, as well as a hypoxic tumor, due to the liver being a relatively hypoxic environment compared to other organs. Trans-arterial chemoembolization (TACE) and trans-arterial embolization (TAE) are locoregional therapies that are part of the treatment guidelines for HCC but can also exacerbate hypoxia in tumors, as seen with HIF-1α upregulation post-hepatic embolization. Hypoxia-activated prodrugs (HAPs) are a novel class of anticancer agent that are selectively activated under hypoxic conditions, potentially allowing for the targeted treatment of hypoxic HCC. Early studies targeting hypoxia show promising results; however, further research is needed to understand the effects of HAPs in combination with embolization in the treatment of HCC. This review aims to summarize current knowledge on the role of hypoxia and HIF-1α in HCC, as well as the potential of HAPs and liver-directed embolization.

show abstract

Recent Advances of Nanocarriers for Effective Delivery of Therapeutic Peptides

Cited by 4 publications

References 183 publications

Anthrax revisited: how assessing the unpredictable can improve biosecurity

Anthrax revisited: how assessing the unpredictable can improve biosecurity

Insights In Biosafety & Biosecurity 2022/2023: Novel Developments, Current Challenges, and Future Perspectives

Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About